Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 67

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 67
---
           
         
 Stockholders’ equity:         
 Preferred stock:         
 Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2025, or December 31, 2024   —   — 
 Common stock, $0.0001 par value, 250,000,000 shares authorized, 56,255,055 shares issued and 54,679,363 shares outstanding as of March 31, 2025; 55,246,401 shares issued and 53,670,709 shares outstanding as of December 31, 2024   5   5 
 Additional paid-in capital   560,471   555,302 
 Treasury stock, at cost   (10,983)  (10,983)
 Accumulated deficit   (508,388)  (505,289)
 Accumulated other comprehensive (loss) income   (82)  631 
 Total stockholders' equity   41,023   39,666 
 Total liabilities and stockholders' equity  $172,708  $178,127 

See accompanying notes to unaudited condensed consolidated financial statements.

       4

      Table of Contents

 ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

      Three months ended March 31,  
   2025    2024  
 Revenue, net  $20,401  $3,425 
 Cost of product revenue (excluding $1,615 and $1,528 in intangible asset amortization for the three months ended March 31, 2025, and March 31, 2024, respectively, shown separately below)   1,345   175 
 Intangible asset amortization   1,615   1,528 
 Operating expenses:         
 Research and development   3,258   12,277 
 Selling, general and administrative   19,545   9,931 
 Total operating expenses   22,803   22,208 
 Loss from operations   (5,362)  (20,486)
 Other income (expense):         
 Interest expense   (1,969